To Increase Patient Access
End Brain Cancer Mobile App to download your number one tool for navigating this disease.

Post Author: Susan Kellner

April 23, 2024
tovorafenib FDA Approval for LGG

(Courtesy of ASCO FDA Alerts) tovorafenib FDA Approval for LGG On April 23, 2024, the Food and Drug Administration granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. […]

Read More
March 29, 2024
ACT NOW: Comment Publicly to Support Coverage of Brain Cancer Treatment in WA State

Take Action. Contact the Washington State Health Care Authority to make an FDA-approved GBM treatment accessible for all patients.

Read More
March 26, 2024
EBCI Looking to Partner with GBM Drug Development Companies to Enhance Our Fight for GBM Patient Access

The End Brain Cancer Initiative (EBCI) will attend the Glioblastoma Drug Development Summit in Boston to insert the patient voice into trial protocols and patient disease education and awareness campaigns.

Read More
March 21, 2024
ACT NOW: Urgent Advocacy Needed for WA State Residents to Expand Access for Cancer Patients

Join us in advocating for coverage for the Tumor Treating Fields device by the Washington State Health Care Authority.

Read More
March 18, 2024
Don't Miss Your Chance to Submit Your 2024 National HOPE Award Nomination

Nominations for the 2024 National HOPE award are due by April 17th. Submit today.

Read More
March 15, 2024
Support Our President’s Podcast Reach & Efforts to Increase Patient Access

We are expanding our disease education efforts with podcast participation.

Read More
March 13, 2024
How I Survived Brain Cancer

With Dellann Elliott Mydland from The EndBrainCancer Initiative.

Read More
March 12, 2024
Corporate Sponsorship Availability to Support EBCI's Mission

Your company can support EBCI's mission by sponsoring our Know All Your Treatment Options (KAYTO) online event, set for May 17, 2024.

Read More
March 7, 2024
Clinical Trial for Pediatric Patients with Diffuse Intrinsic Pontine Glioma (DIPG)

SonALAsense is currently recruiting patients in a Phase 1/2 Clinical Trial in DIPG, which uses Sonodynamic Therapy (SDT).

Read More
March 4, 2024
2024 National HOPE Award Nominations Now Open

Nominations are being sought for the 2024 National HOPE award.

Read More
February 29, 2024
A Message from Our CEO: Help DCVax®-L Gain FDA Approval

DCVax®-L represents a novel form of immunotherapy, developed by Northwest Biotherapeutics, which could be a new treatment option for glioblastoma. Join the movement to seek FDA approval.

Read More
February 15, 2024
Access All of Your Medical Records with xCures

xCures can work with your doctor to help you access new treatments by providing access to your electronic medical records.

Read More
1 2 3 8


Enhancing patient outcomes by expanding FDA-approved treatment modalities and fueling research in the pharma/bio/life sciences, device & diagnostic industries and by closing the existing GAP from initial diagnosis to IMMEDIATE AND EXPANDED ACCESS to specialists, researchers, advanced & innovative treatments, clinical trials and critical care with the ultimate goal of improving patient outcomes through updating and improving WHO & NCCN Guidelines and clinical practices related to Standard of Care for brain cancer patients.

TAX ID:26-2185614
corporate partners
upcoming events
About us
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram